Literature DB >> 28941093

Staging in bipolar disorder: from theoretical framework to clinical utility.

Michael Berk1,2,3,4,5, Robert Post6, Aswin Ratheesh3,4, Emma Gliddon1, Ajeet Singh1, Eduard Vieta7, Andre F Carvalho8,9, Melanie M Ashton1, Lesley Berk1,2, Susan M Cotton3,4, Patrick D McGorry3,4, Brisa S Fernandes1, Lakshmi N Yatham10, Seetal Dodd1,2,3.   

Abstract

Illness staging is widely utilized in several medical disciplines to help predict course or prognosis, and optimize treatment. Staging models in psychiatry in general, and bipolar disorder in particular, depend on the premise that psychopathology moves along a predictable path: an at-risk or latency stage, a prodrome progressing to a first clinical threshold episode, and one or more recurrences with the potential to revert or progress to late or end-stage manifestations. The utility and validity of a staging model for bipolar disorder depend on its linking to clinical outcome, treatment response and neurobiological measures. These include progressive biochemical, neuroimaging and cognitive changes, and potentially stage-specific differences in response to pharmacological and psychosocial treatments. Mechanistically, staging models imply the presence of an active disease process that, if not remediated, can lead to neuroprogression, a more malignant disease course and functional deterioration. Biological elements thought to be operative in bipolar disorder include a genetic diathesis, physical and psychic trauma, epigenetic changes, altered neurogenesis and apoptosis, mitochondrial dysfunction, inflammation, and oxidative stress. Many available agents, such as lithium, have effects on these targets. Staging models also suggest the utility of stage-specific treatment approaches that may not only target symptom reduction, but also impede illness neuroprogression. These treatment approaches range from prevention for at-risk individuals, to early intervention strategies for prodromal and newly diagnosed individuals, complex combination therapy for rapidly recurrent illness, and palliative-type approaches for those at chronic, late stages of illness. There is hope that prompt initiation of potentially disease modifying therapies may preclude or attenuate the cognitive and structural changes seen in the later stages of bipolar disorder. The aims of this paper are to: a) explore the current level of evidence supporting the descriptive staging of the syndromal pattern of bipolar disorder; b) describe preliminary attempts at validation; c) make recommendations for the direction of further studies; and d) provide a distillation of the potential clinical implications of staging in bipolar disorder within a broader transdiagnostic framework.
© 2017 World Psychiatric Association.

Entities:  

Keywords:  Bipolar disorder; biological markers; clinical staging; cognitive functioning; early intervention; kindling; lithium; neuroprogression; neuroprotection; transdiagnostic framework; treatment outcome

Year:  2017        PMID: 28941093      PMCID: PMC5608827          DOI: 10.1002/wps.20441

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  98 in total

1.  Are we missing opportunities for early intervention in bipolar disorder?

Authors:  Craig A Macneil; Karen Hallam; Philippe Conus; Lisa Henry; Linda Kader; Michael Berk
Journal:  Expert Rev Neurother       Date:  2012-01       Impact factor: 4.618

Review 2.  Staging bipolar disorder.

Authors:  Eduard Vieta; M Reinares; A R Rosa
Journal:  Neurotox Res       Date:  2010-05-12       Impact factor: 3.911

3.  Quieting the affective storm of borderline personality disorder.

Authors:  Marianne Goodman; Erin A Hazlett; Antonia S New; Harold W Koenigsberg; Larry Siever
Journal:  Am J Psychiatry       Date:  2009-05       Impact factor: 18.112

4.  Diagnosing bipolar disorder: Defining thresholds and setting boundaries.

Authors:  Gin S Malhi; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2014-06       Impact factor: 5.744

5.  Hypomania: hype or mania?

Authors:  Gin S Malhi; K N Roy Chengappa; Samuel Gershon; Joseph F Goldberg
Journal:  Bipolar Disord       Date:  2010-12       Impact factor: 6.744

Review 6.  The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications.

Authors:  S Moylan; M Maes; N R Wray; M Berk
Journal:  Mol Psychiatry       Date:  2012-04-24       Impact factor: 15.992

7.  Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome.

Authors:  Jan-Marie Kozicky; Alexander McGirr; David J Bond; Marjorie Gonzalez; Leonardo E Silveira; Kamyar Keramatian; Ivan J Torres; Raymond W Lam; Lakshmi N Yatham
Journal:  Bipolar Disord       Date:  2016-09       Impact factor: 6.744

Review 8.  Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence.

Authors:  Lucy J Robinson; I Nicol Ferrier
Journal:  Bipolar Disord       Date:  2006-04       Impact factor: 6.744

Review 9.  Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena.

Authors:  Robert M Post
Journal:  Neurosci Biobehav Rev       Date:  2007-04-24       Impact factor: 8.989

Review 10.  A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.

Authors:  Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2016-04-09       Impact factor: 8.989

View more
  37 in total

Review 1.  [Psychotherapy for people with bipolar disorders : An overview of evidence-based procedures and new developments].

Authors:  T J Stamm; L-M Sondergeld; G Juckel; M Bauer
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

2.  Intrinsic functional connectivity correlates of person-level risk for bipolar disorder in offspring of affected parents.

Authors:  Danella M Hafeman; Henry W Chase; Kelly Monk; Lisa Bonar; Mary Beth Hickey; Alicia McCaffrey; Simona Graur; Anna Manelis; Cecile D Ladouceur; John Merranko; David A Axelson; Benjamin I Goldstein; Tina R Goldstein; Boris Birmaher; Mary L Phillips
Journal:  Neuropsychopharmacology       Date:  2018-11-08       Impact factor: 7.853

3.  Ethical Issues in the Diagnosis and Treatment of Bipolar Disorders.

Authors:  Michael J Ostacher
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

5.  ER-mitochondria communication is involved in NLRP3 inflammasome activation under stress conditions in the innate immune system.

Authors:  Ana Catarina Pereira; Jessica De Pascale; Rosa Resende; Susana Cardoso; Isabel Ferreira; Bruno Miguel Neves; Mylène A Carrascal; Mónica Zuzarte; Nuno Madeira; Sofia Morais; António Macedo; Anália do Carmo; Paula I Moreira; Maria Teresa Cruz; Cláudia F Pereira
Journal:  Cell Mol Life Sci       Date:  2022-03-28       Impact factor: 9.261

Review 6.  Pharmacological treatment of adult bipolar disorder.

Authors:  Ross J Baldessarini; Leonardo Tondo; Gustavo H Vázquez
Journal:  Mol Psychiatry       Date:  2018-04-20       Impact factor: 15.992

7.  Preventive psychiatry: a blueprint for improving the mental health of young people.

Authors:  Paolo Fusar-Poli; Christoph U Correll; Celso Arango; Michael Berk; Vikram Patel; John P A Ioannidis
Journal:  World Psychiatry       Date:  2021-06       Impact factor: 79.683

8.  Mitochondrial Alterations in Fibroblasts of Early Stage Bipolar Disorder Patients.

Authors:  Ana P Marques; Rosa Resende; Diana F Silva; Mariana Batista; Daniela Pereira; Brigite Wildenberg; Sofia Morais; António Macedo; Cláudia Pais; Joana B Melo; Nuno Madeira; Cláudia F Pereira
Journal:  Biomedicines       Date:  2021-05-07

9.  Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden.

Authors:  Julia Martini; Karolina Leopold; Steffi Pfeiffer; Christina Berndt; Anne Boehme; Veit Roessner; Paolo Fusar-Poli; Allan H Young; Christoph U Correll; Michael Bauer; Andrea Pfennig
Journal:  Int J Bipolar Disord       Date:  2021-07-02

10.  Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.

Authors:  Masoud Kamali; Samantha Pegg; Jessica A Janos; William V Bobo; Benjamin Brody; Keming Gao; Terence A Ketter; Susan L McElroy; Melvin G McInnis; Dustin J Rabideau; Noreen A Reilly-Harrington; Richard C Shelton; Louisa G Sylvia; Mauricio Tohen; Andrew Nierenberg
Journal:  J Psychiatr Res       Date:  2021-06-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.